Cite
Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro .
MLA
Herranz, Raquel, et al. “Bladder Cancer Patients Have Increased NETosis and Impaired DNaseI-Mediated NET Degradation That Can Be Therapeutically Restored in Vitro .” Frontiers in Immunology, vol. 14, May 2023, p. 1171065. EBSCOhost, https://doi.org/10.3389/fimmu.2023.1171065.
APA
Herranz, R., Oto, J., Hueso, M., Plana, E., Cana, F., Castaño, M., Cordón, L., Ramos-Soler, D., Bonanad, S., Vera-Donoso, C. D., Martínez-Sarmiento, M., & Medina, P. (2023). Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro . Frontiers in Immunology, 14, 1171065. https://doi.org/10.3389/fimmu.2023.1171065
Chicago
Herranz, Raquel, Julia Oto, Marta Hueso, Emma Plana, Fernando Cana, María Castaño, Lourdes Cordón, et al. 2023. “Bladder Cancer Patients Have Increased NETosis and Impaired DNaseI-Mediated NET Degradation That Can Be Therapeutically Restored in Vitro .” Frontiers in Immunology 14 (May): 1171065. doi:10.3389/fimmu.2023.1171065.